CROI 2019 - CROI 2019

ORAL ABSTRACT: AIDS MALIGNANCIES AND KSHV

"HPV VACCINE WITH LEEP DID NOT PREVENT RECURRENT CERVICAL HSIL IN HIV-INFECTED WOMEN" by Cindy Firnhaber of University of Colorado Medical Center, Aurora, CO, USA

ORAL ABSTRACT: AIDS MALIGNANCIES AND KSHV

"OPTIMAL LUNG CANCER SCREENING CRITERIA AMONG PERSONS LIVING WITH HIV" by Subhashini A Sellers of University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

ORAL ABSTRACT: AIDS MALIGNANCIES AND KSHV

"HIV IS ASSOCIATED WITH DECREASED BREAST CANCER SURVIVAL: A PROSPECTIVE COHORT STUDY" by Katrin Sara Sadigh of Brigham and Women's Hospital, Boston, MA, USA

ORAL ABSTRACT: AIDS MALIGNANCIES AND KSHV

"LONG-TERM OUTCOMES OF 58 PATIENTS WITH HIV AND KSHV+ MULTICENTRIC CASTLEMAN DISEASE" by Ramya Ramaswami of HIV AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

ORAL ABSTRACT: AIDS MALIGNANCIES AND KSHV

"REDUCTION OF KAPOSI SARCOMA–ASSOCIATED HERPESVIRUS LATENCY USING CRISPR-CAS9" by For Yue Tso of University of Nebraska - Lincoln, Lincoln, NE, USA

ORAL ABSTRACT: AIDS MALIGNANCIES AND KSHV

"QUANTIFICATION OF KSHV DNA AS A DIAGNOSTIC TEST FOR KAPOSI SARCOMA IN AFRICA" by Aggrey Semeere of Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda

ORAL ABSTRACT: AIDS MALIGNANCIES AND KSHV

"TWO NOVEL POTENTIAL THERAPEUTIC TARGETS IN THE KSHV LIFE CYCLE" by Thomas Schulz of Medizinischen Hochschule Hannover, Hannover, Germany

ORAL ABSTRACT: STRATEGIES FOR HIV CURE

"TARGETING THE NONCANONICAL NF-ΚB PATHWAY REVERSES SIV LATENCY" by Maud Mavigner of Emory University School of Medicine, Atlanta, GA, USA

ORAL ABSTRACT: STRATEGIES FOR HIV CURE

"NONSUPPRESSIBLE VIREMIA ON ART FROM LARGE CELL CLONES CARRYING INTACT PROVIRUSES" by Elias K Halvas of University of Pittsburgh, Pittsburgh, PA, USA

ORAL ABSTRACT: STRATEGIES FOR HIV CURE

"EX VIVO AND IN VIVO EDITING OF THE SIV GENOME IN NONHUMAN PRIMATES BY CRISPR-CAS9" by Tricia H. Burdo of Temple University School of Medicine, Philadelphia, PA, USA

ORAL ABSTRACT: STRATEGIES FOR HIV CURE

"DELAYED VIRAL REBOUND DURING ATI AFTER INFUSION OF CCR5 ZFN-TREATED CD4 T CELLS" by Pablo Tebas of University of Pennsylvania, Philadelphia, PA, USA

ORAL ABSTRACT: STRATEGIES FOR HIV CURE

"MULTIDOSE IV ROMIDEPSIN: NO INCREASED HIV-1 EXPRESSION IN PERSONS ON ART, ACTG A5315" by Deborah McMahon of University of Pittsburgh, Pittsburgh, PA, USA

ORAL ABSTRACT: STRATEGIES FOR HIV CURE

"PEMBROLIZUMAB INDUCES HIV LATENCY REVERSAL IN HIV+ INDIVIDUALS ON ART WITH CANCER" by Thomas S Uldrick of Fred Hutchinson Cancer Research Center, Seattle, WA, USA

ORAL ABSTRACT: STRATEGIES FOR HIV CURE

"POTENT ANTIVIRAL ACTIVITY OF TRISPECIFIC BROADLY NEUTRALIZING HIV ANTIBODIES" by Amarendra Pegu of Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA

ORAL ABSTRACT: STRATEGIES FOR HIV CURE

"SUSTAINED HIV-1 REMISSION FOLLOWING HOMOZYGOUS CCR5 DELTA32 ALLOGENIC HSCT" by Ravindra K Gupta of University College London, London, United Kingdom

ORAL ABSTRACT: NONCOMMUNICABLE DISEASES IN TREATED HIV

"BREAKING BONES IS BAD: INCIDENT FRACTURE AND MORTALITY IN THE HIV OUTPATIENT STUDY" by Linda Ann Battalora of Colorado School of Mines, Golden, CO, USA

ORAL ABSTRACT: NONCOMMUNICABLE DISEASES IN TREATED HIV

"COPD AND THE RISK FOR MYOCARDIAL INFARCTION BY TYPE IN PEOPLE LIVING WITH HIV" by Kristina Crothers of University of Washington, Seattle, WA, USA

ORAL ABSTRACT: NONCOMMUNICABLE DISEASES IN TREATED HIV

"SUDDEN CARDIAC DEATH AMONG HIV-INFECTED AND -UNINFECTED VETERANS" by Matthew Freiberg of Vanderbilt University School of Medicine, Nashville, TN, USA

ORAL ABSTRACT: NONCOMMUNICABLE DISEASES IN TREATED HIV

"HIV POST SCD STUDY: 80% HIGHER RATE OF AUTOPSY-DEFINED SUDDEN ARRHYTHMIC DEATH IN HIV" by Zian H. Tseng of UCSF, San Francisco, CA, USA

ORAL ABSTRACT: NONCOMMUNICABLE DISEASES IN TREATED HIV

"CABOTEGRAVIR IS NOT ASSOCIATED WITH WEIGHT GAIN IN HIV-NEGATIVE INDIVIDUALS: HPTN 077" by Raphael J. Landovitz of University of California Los Angeles, Los Angeles, CA, USA

ORAL ABSTRACT: NONCOMMUNICABLE DISEASES IN TREATED HIV

"ASSESSING THE PROBIOTIC EFFECT IN TREATED HIV: RESULTS OF ACTG A5350" by Edgar Turner Overton of University of Alabama, Birmingham, AL, USA

ORAL ABSTRACT: NONCOMMUNICABLE DISEASES IN TREATED HIV

"FACTOR X INHIBITION REDUCES COAGULATION BUT NOT INFLAMMATION IN PERSONS WITH HIV" by Jason V Baker of Hennepin Healthcare Research Institute (U of MN), Minneapolis, MN, USA

ORAL ABSTRACT: NONCOMMUNICABLE DISEASES IN TREATED HIV

"SAFETY, TOLERABILITY AND IMMUNOLOGIC ACTIVITY OF RUXOLITINIB ADDED TO SUPPRESSIVE ART" by Vincent C. Marconi of School of Medicine, Emory University, Atlanta, GA, USA

ORAL ABSTRACT: CRITICAL ISSUES IN MATERNAL AND PEDIATRIC HEALTH

"RANDOMIZED TRIAL OF RALTEGRAVIR-ART VS EFAVIRENZ-ART WHEN INITIATED DURING PREGNANCY" by Mark Mirochnick of Boston University School of Medicine, Hingham, MA, USA

ORAL ABSTRACT: CRITICAL ISSUES IN MATERNAL AND PEDIATRIC HEALTH

"RCT OF DOLUTEGRAVIR VS EFAVIRENZ-BASED THERAPY INITIATED IN LATE PREGNANCY: DOLPHIN-2" by Saye Khoo of University of Liverpool Institute of Translational Medicine, Liverpool, United Kingdom

ORAL ABSTRACT: CRITICAL ISSUES IN MATERNAL AND PEDIATRIC HEALTH

"MATERNAL HBV VIREMIA IS ASSOCIATED WITH ADVERSE INFANT OUTCOMES IN HIV/HBV WOMEN" by Debika Bhattacharya of University of California Los Angeles, Los Angeles, CA, USA

ORAL ABSTRACT: CRITICAL ISSUES IN MATERNAL AND PEDIATRIC HEALTH

"IMPACT OF IMPROVED NUTRITION/SANITATION ON NEURODEVELOPMENT OF HIV-EXPOSED CHILDREN" by Robert Ntozini of Zvitambo Institute for Maternal and Child Health Research, Harare, Zimbabwe

ORAL ABSTRACT: CRITICAL ISSUES IN MATERNAL AND PEDIATRIC HEALTH

"UNIQUE IMMUNOLOGICAL AND VIROLOGICAL FEATURES OF EARLY TREATED HIV-INFECTED NEWBORNS" by Pilar Garcia Broncano of Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA

ORAL ABSTRACT: CRITICAL ISSUES IN MATERNAL AND PEDIATRIC HEALTH

"NEONATAL ART < 7 DAYS VS 7-28 DAYS REDUCED TIME TO SUPPRESSION" by Sara Dominguez Rodriguez of Fundación Investigación Biomédica Hospital 12 Octubre, Madrid, Spain

ORAL ABSTRACT: CRITICAL ISSUES IN MATERNAL AND PEDIATRIC HEALTH

"SAFETY AND PHARMACOKINETICS OF MONOCLONAL ANTIBODY, VRC01LS, IN HIV-EXPOSED NEWBORNS" by Elizabeth J McFarland of University of Colorado School of Medicine, Aurora, CO, USA

ORAL ABSTRACT: CRITICAL ISSUES IN MATERNAL AND PEDIATRIC HEALTH

"BICTEGRAVIR/FTC/TAF SINGLE-TABLET REGIMEN IN ADOLESCENTS & CHILDREN: WEEK 48 RESULTS" by Aditya Gaur of St. Jude Children’s Research Hospital, Memphis, TN, USA

ORAL ABSTRACT: STRANGE BEDFELLOWS: STIs, CONTRACEPTION, AND TRIALS OF HIV TESTING

"INCIDENT SYPHILIS RATES AND PREDICTORS IN US WOMEN WITH HIV, 2005-2016" by Jodie Dionne-Odom of University of Alabama at Birmingham, Birmingham, AL, USA

ORAL ABSTRACT: STRANGE BEDFELLOWS: STIs, CONTRACEPTION, AND TRIALS OF HIV TESTING

"PREPARING FOR PREP IN ENGLAND: PREVALENCE AND INCIDENCE OF HIV AND BACTERIAL STIS" by Dana Ogaz of Public Health England, London, United Kingdom

ORAL ABSTRACT: STRANGE BEDFELLOWS: STIs, CONTRACEPTION, AND TRIALS OF HIV TESTING

"EXPANDING TESTING STRATEGIES IN PARIS: A FREE POSTAL COMPREHENSIVE STI TEST KIT" by Heloise M Delagreverie of Hôpital Saint Louis - APHP, Paris, France

ORAL ABSTRACT: STRANGE BEDFELLOWS: STIs, CONTRACEPTION, AND TRIALS OF HIV TESTING

"RANDOMIZED CONTROLLED TRIAL OF INTRAUTERINE DEVICE SAFETY IN WOMEN LIVING WITH HIV" by Catherine S Todd of FHI360, Durham, NC, USA

ORAL ABSTRACT: STRANGE BEDFELLOWS: STIs, CONTRACEPTION, AND TRIALS OF HIV TESTING

"DOUBLE-DOSE LEVONORGESTREL IMPLANT DOES NOT FULLY OVERCOME INTERACTION WITH EFAVIRENZ" by Kimberly K. Scarsi of University of Nebraska, Omaha, NE, USA

ORAL ABSTRACT: STRANGE BEDFELLOWS: STIs, CONTRACEPTION, AND TRIALS OF HIV TESTING

"PHARMACOGENETICS WORSENS AN ADVERSE ANTIRETROVIRAL-HORMONAL CONTRACEPTIVE INTERACTION" by David Haas of Vanderbilt University School of Medicine, Nashville, TN, USA

ORAL ABSTRACT: STRANGE BEDFELLOWS: STIs, CONTRACEPTION, AND TRIALS OF HIV TESTING

"POINT-OF-CARE VIRAL LOAD TESTING IMPROVES HIV VIRAL SUPPRESSION AND RETENTION IN CARE" by Paul K Drain of University of Washington, Seattle, WA, USA

ORAL ABSTRACT: STRANGE BEDFELLOWS: STIs, CONTRACEPTION, AND TRIALS OF HIV TESTING

"EFFECT OF THE HITS INTERVENTION ON HIV TESTING UPTAKE AMONG MEN IN SOUTH AFRICA" by Hae-Young Kim of Africa Health Research Institute, Durban, South Africa

ORAL ABSTRACT: VIRUS-CELL INTERACTION

"ORAL ABSTRACT MODERATOR" by Stefan Sarafianos of Emory University School of Medicine, Atlanta, GA, USA

ORAL ABSTRACT: VIRUS-CELL INTERACTION

"A VIRUS-PACKAGEABLE CRISPR SCREEN IDENTIFIES HIV RESTRICTION AND DEPENDENCY FACTORS" by Molly Ohainle of Fred Hutchinson Cancer Research Center, Seattle, WA, USA

ORAL ABSTRACT: VIRUS-CELL INTERACTION

"A FUNCTIONAL MAP OF HIV-HOST INTERACTIONS IN PRIMARY HUMAN CD4+ T CELLS" by Judd F Hultquist of Northwestern University, Chicago, IL, USA

ORAL ABSTRACT: VIRUS-CELL INTERACTION

"HIV-1 COMPLEXES TRAFFIC WITH HOST CPSF6 ON MICROTUBULES PRIOR TO NUCLEAR ENTRY" by Zandrea Ambrose of University of Pittsburgh, Pittsburgh, PA, USA

ORAL ABSTRACT: VIRUS-CELL INTERACTION

"HIV-1 CAPSID DETERMINANTS THAT INFLUENCE NUCLEAR ENVELOPE DOCKING AND NUCLEAR IMPORT" by Mohamed Husen Munshi of National Cancer Institute, Frederick, MD, USA

ORAL ABSTRACT: VIRUS-CELL INTERACTION

"SINGLE HIV-1 VIRUS IMAGING WITH CA-EGFP QUESTIONS A ROLE OF NUCLEAR CA IN INTEGRATION" by Frauke Christ of Katholieke University Leuven, Leuven, Belgium

ORAL ABSTRACT: VIRUS-CELL INTERACTION

"DISRUPTION OF HIV-1 LTR SEQUENCE BY A NUCLEOCAPSID MUTATION LEADS TO DTG RESISTANCE" by Atsuko Hachiya of National Hospital Organization Nagoya Medical Center, Aichi, Japan

ORAL ABSTRACT: VIRUS-CELL INTERACTION

"INTEGRASE (IN) TETRAMERS ARE THE AUTHENTIC TARGETS FOR ALLOSTERIC HIV-1 IN INHIBITORS" by Pratibha Chowdary Koneru of University of Colorado, Aurora, CO, USA

ORAL ABSTRACT: VIRUS-CELL INTERACTION

"TARGETING VIRUS ENV AND CD44 IMPROVES BBAB AVIDITY AND NEUTRALIZATION POTENCY" by Djin-Ye Oh of Aaron Diamond AIDS Research Center, New York, NY, USA

ORAL ABSTRACT: TB: FROM CONTACT TO CURE AND BEYOND

"IPT AND PREGNANCY OUTCOMES IN HIV-POSITIVE WOMEN: THE TSHEPISO COHORT" by Nicole Salazar-Austin of Johns Hopkins University School of Medicine, Baltimore, MD, USA

ORAL ABSTRACT: TB: FROM CONTACT TO CURE AND BEYOND

"POTENTIAL CONCERN FOR TIMING OF DMPA INJECTION AMONG WOMEN TREATED FOR HIV AND TB" by Rosie Mngqibisa of Enhancing Care Initiative, Durban RSA, South Africa

ORAL ABSTRACT: TB: FROM CONTACT TO CURE AND BEYOND

"IMPROVING CHILD TUBERCULOSIS CONTACT MANAGEMENT IN LESOTHO" by Yael Hirsch-Moverman of Columbia University, Mailman School of Public Health, New York, NY, USA

ORAL ABSTRACT: TB: FROM CONTACT TO CURE AND BEYOND

"SAFETY & PK OF WEEKLY RIFAPENTINE/ISONIAZID (3HP) IN ADULTS WITH HIV ON DOLUTEGRAVIR" by Kelly E Dooley of Johns Hopkins University, Baltimore, MD, USA

ORAL ABSTRACT: TB: FROM CONTACT TO CURE AND BEYOND

"PHARMACOKINETICS AND SAFETY OF ADJUSTED DARUNAVIR/RITONAVIR WITH RIFAMPIN IN PLWH" by Gary Maartens of University of Cape Town, Cape Town, South Africa

ORAL ABSTRACT: TB: FROM CONTACT TO CURE AND BEYOND

"EARLY BACTERICIDAL ACTIVITY OF HIGH-DOSE ISONIAZID AGAINST MULTIDRUG-RESISTANT TB" by Kelly E Dooley of Johns Hopkins University, Baltimore, MD, USA

ORAL ABSTRACT: TB: FROM CONTACT TO CURE AND BEYOND

"LONG-TERM MORTALITY AFTER TUBERCULOSIS CURE IN THE CIPRA HT-001 TRIAL" by Yvetot Joseph of Les Centres GHESKIO, Haiti, Port-au-Prince, Haiti

ORAL ABSTRACT: TB: FROM CONTACT TO CURE AND BEYOND

"QT EFFECTS OF BEDAQUILINE, DELAMANID OR BOTH IN MDR-TB PATIENTS: THE DELIBERATE TRIAL" by Gary Maartens of University of Cape Town, Cape Town, South Africa

ORAL ABSTRACT: HEPATITIS C: NOW YOU SEE ME; SOON YOU WON'T

"FALL IN HCV INCIDENCE IN HIV+ MSM IN LONDON FOLLOWING WIDER ACCESS TO DAA THERAPY" by Lucy Jane Garvey of Imperial College Healthcare NHS Trust, London, United Kingdom

ORAL ABSTRACT: HEPATITIS C: NOW YOU SEE ME; SOON YOU WON'T

"HCV REINFECTION AMONG HIV-INFECTED MSM IN NEW YORK CITY" by Daniel S. Fierer of Icahn School of Medicine at Mount Sinai, New York, NY, USA

ORAL ABSTRACT: HEPATITIS C: NOW YOU SEE ME; SOON YOU WON'T

"A PHASE 1 STUDY OF LEDIPASVIR/SOFOSBUVIR IN PREGNANT WOMEN WITH HEPATITIS C VIRUS" by Catherine Anne Chappell of Magee-Womens Hospital of UPMC, Pittsburgh, PA, USA

ORAL ABSTRACT: HEPATITIS C: NOW YOU SEE ME; SOON YOU WON'T

"INCIDENT DIABETES AND GLUCOSE CONTROL AFTER HCV TREATMENT WITH DAAS IN ERCHIVES" by Adeel Ajwad Butt of Weill Cornell Medical College, New York, NY, USA

ORAL ABSTRACT: HEPATITIS C: NOW YOU SEE ME; SOON YOU WON'T

"INTRAHEPATIC HEPATITIS C KINETICS WITH DIRECT-ACTING ANTIVIRALS IN HIV COINFECTION" by Ashwin Balagopal of Johns Hopkins University, Baltimore, MD, USA

ORAL ABSTRACT: HEPATITIS C: NOW YOU SEE ME; SOON YOU WON'T

"HIV VIREMIA AND LOW CD4+ INCREASE HCC RISK IN THOSE WITHOUT ADVANCED LIVER FIBROSIS" by Jessie Torgersen of University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

ORAL ABSTRACT: HEPATITIS C: NOW YOU SEE ME; SOON YOU WON'T

"SINGLE HEPATOCYTE ANALYSIS IN HIV-HBV COINFECTION SHOWS HBV TRANSCRIPTION SILENCING" by Chloe Thio of Johns Hopkins University School of Medicine, Baltimore, MD, USA

ORAL ABSTRACT: TESTING, VIRAL SUPPRESSION, AND IMPACT

"IMPACT OF UNIVERSAL TESTING AND TREATMENT IN ZAMBIA AND SOUTH AFRICA: HPTN071(POPART)" by Richard J Hayes of London School of Hygiene and Tropical Medicine, London, United Kingdom

ORAL ABSTRACT: TESTING, VIRAL SUPPRESSION, AND IMPACT

"A RANDOMIZED TRIAL ON INDEX HIV SELF-TESTING FOR PARTNERS OF ART CLIENTS IN MALAWI" by Kathryn Dovel of University of California Los Angeles, Westwood, CA, USA

ORAL ABSTRACT: TESTING, VIRAL SUPPRESSION, AND IMPACT

"VIRAL LOAD SUPPRESSION AND YIELD OF HIV TESTS ARE SPATIALLY CORRELATED, KENYA 2015-17" by Anthony Waruru of U.S. Centers for Disease Control and Prevention, Nairobi, Kenya

ORAL ABSTRACT: TESTING, VIRAL SUPPRESSION, AND IMPACT

"HIV TESTING, TREATMENT, AND VIRAL SUPPRESSION COVERAGE IN A CLUSTER-RANDOMIZED TRIAL" by Kathleen Wirth of Harvard T.H. Chan School of Public Health, Boston, MA, USA

ORAL ABSTRACT: TESTING, VIRAL SUPPRESSION, AND IMPACT

"FACTORS ASSOCIATED WITH PERSISTENT VIREMIA WITH UNIVERSAL “TEST & TREAT” IN UGANDA" by Eshan Uday Patel of Johns Hopkins University, Baltimore, MD, USA

ORAL ABSTRACT: TESTING, VIRAL SUPPRESSION, AND IMPACT

"VIROLOGIC FAILURE, LOW-LEVEL VIREMIA, AND VIRAL BLIP AFTER HIV RNA SUPPRESSION" by Jennifer S Lee of Johns Hopkins University, Baltimore, MD, USA

ORAL ABSTRACT: TESTING, VIRAL SUPPRESSION, AND IMPACT

"FIFTY-PERCENT REDUCTION IN HIV INCIDENCE IN CHOKWE DISTRICT, MOZAMBIQUE, 2014-2017" by Duncan Alan MacKellar of CDC, Lilburn, GA, USA

ORAL ABSTRACT: TESTING, VIRAL SUPPRESSION, AND IMPACT

"A MODEL IMPACT ANALYSIS OF PREP AND TASP IN FSW DEMONSTRATION PROJECT IN BENIN" by Lily Geidelberg of Imperial College London, London, UT, United Kingdom

ORAL ABSTRACT: NEW OPTIONS AND OPPORTUNITIES IN PrEP

"PROTECTION AGAINST PENILE OR INTRAVENOUS SHIV CHALLENGES BY BNAB 10-1074 OR 3BNC117" by David A Garber of Centers for Disease Control and Prevention, Atlanta, GA, USA

ORAL ABSTRACT: NEW OPTIONS AND OPPORTUNITIES IN PrEP

"PROTECTION AGAINST VAGINAL SHIV INFECTION WITH AN INSERT CONTAINING TAF AND EVG" by Charles Dobard of CDC, Atlanta, GA, USA

ORAL ABSTRACT: NEW OPTIONS AND OPPORTUNITIES IN PrEP

"MODERATE EFFICACY OF ORAL SINGLE-AGENT TAF AGAINST VAGINAL SHIV INFECTION IN MACAQUES" by Ivana Massud of Centres for Disease Control and Prevention, Atlanta, GA, USA

ORAL ABSTRACT: NEW OPTIONS AND OPPORTUNITIES IN PrEP

"LYMPHOID TISSUE PHARMACOKINETICS OF TENOFOVIR-ALAFENAMIDE VS -DISOPROXIL FUMARATE" by Courtney V. Fletcher of University of Nebraska Medical Center, Omaha, NE, USA

ORAL ABSTRACT: NEW OPTIONS AND OPPORTUNITIES IN PrEP

"THE PHASE 3 DISCOVER STUDY: DAILY F/TAF OR F/TDF FOR HIV PREEXPOSURE PROPHYLAXIS" by Charles B Hare of Kaiser Permanente San Francisco Medical Center, San Francisco, CA, USA

ORAL ABSTRACT: NEW OPTIONS AND OPPORTUNITIES IN PrEP

"USING EHR DATA TO IDENTIFY POTENTIAL PREP CANDIDATES IN A LARGE HEALTH CARE SYSTEM" by Julia L. Marcus of Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA

ORAL ABSTRACT: NEW OPTIONS AND OPPORTUNITIES IN PrEP

"PERSISTENCE WITH HIV PREEXPOSURE PROPHYLAXIS IN THE UNITED STATES, 2012-2016" by Ya-Lin A Huang of Centers for Disease Control and Prevention, Atlanta, GA, USA

ORAL ABSTRACT: NEW OPTIONS AND OPPORTUNITIES IN PrEP

"IMPACT OF PREP ON DRUG RESISTANCE AND ACUTE HIV INFECTION, NEW YORK CITY, 2015-2017" by Kavita Misra of New York City Department of Health and Mental Hygiene, Long Island City, NY, USA

ORAL ABSTRACT: SUPPRESSIVE ART AND THE CNS: SWITCHES, OUTCOMES, AND BIOMARKERS

"BRAIN CONNECTIVITY IN NEUROLOGICALLY ASYMPTOMATIC PEOPLE WITH HIV SWITCHING ART" by Jaime H Vera of Brighton and Sussex Medical School, University of Sussex, Brighton, East Sussex, United Kingdom

ORAL ABSTRACT: SUPPRESSIVE ART AND THE CNS: SWITCHES, OUTCOMES, AND BIOMARKERS

"DEEP-LEARNING CEREBRAL BLOOD FLOW FOR COGNITIVE-IMPAIRMENT CLASSIFICATION IN HIV" by Patrick Luckett of Washington University in St Louis, St Louis, MO, USA

ORAL ABSTRACT: SUPPRESSIVE ART AND THE CNS: SWITCHES, OUTCOMES, AND BIOMARKERS

"HOST GLYCOMIC DETERMINANTS OF HIV-ASSOCIATED NEUROCOGNITIVE IMPAIRMENT DURING THERAPY" by Leila Bertoni Giron of The Wistar Institute, Philadelphia, PA, USA

ORAL ABSTRACT: SUPPRESSIVE ART AND THE CNS: SWITCHES, OUTCOMES, AND BIOMARKERS

"CSF SCD30 ELEVATION DESPITE SUPPRESSIVE ART SUGGESTS CNS HIV PERSISTENCE" by Michael Peluso of University of California - San Francisco, San Francisco, CA, USA

ORAL ABSTRACT: SUPPRESSIVE ART AND THE CNS: SWITCHES, OUTCOMES, AND BIOMARKERS

"CSF HIV RNA DETECTED AT <20 COPIES/ML ASSOCIATES WITH BLOOD-BRAIN BARRIER MEASURES" by Shelli Farhadian of Yale School of Medicine, New Haven, CT, USA

ORAL ABSTRACT: SUPPRESSIVE ART AND THE CNS: SWITCHES, OUTCOMES, AND BIOMARKERS

"EFFECT ON PLASMA NFL, A MARKER OF NEURONAL INJURY, AFTER SWITCHING FROM TDF TO TAF" by Linn Hermansson of Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden

ORAL ABSTRACT: SUPPRESSIVE ART AND THE CNS: SWITCHES, OUTCOMES, AND BIOMARKERS

"CARDIOVASCULAR RISK SCORES PREDICT LONGITUDINAL COGNITIVE FUNCTION IN OLDER PLHIV" by Felicia C Chow of UCSF, San Francisco, CA, USA

ORAL ABSTRACT: SUPPRESSIVE ART AND THE CNS: SWITCHES, OUTCOMES, AND BIOMARKERS

"OBESITY IS INDEPENDENTLY ASSOCIATED WITH NEUROCOGNITIVE DECLINE IN HIV" by Kristine M Erlandson of University of Colorado, Aurora, CO, USA

ORAL ABSTRACT: HIV/SIV AND THE IMMUNE SYSTEM: AN INTIMATE DANCE

"HIGH HIV VIRAL BURDEN PERSISTS IN CXCR3+ GCTFH DESPITE VERY EARLY ART INITIATION" by Zaza Ndhlovu of Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA

ORAL ABSTRACT: HIV/SIV AND THE IMMUNE SYSTEM: AN INTIMATE DANCE

"SIROLIMUS REDUCES T-CELL CYCLING AND IMMUNE CHECKPOINT MARKER EXPRESSION, ACTG A5337" by Timothy J Henrich of UCSF, San Francisco, CA, USA

ORAL ABSTRACT: HIV/SIV AND THE IMMUNE SYSTEM: AN INTIMATE DANCE

"PD-1 AND CTLA-4 BLOCKADE IN MACAQUES INDUCES T-CELL EXPANSION AND SIV REACTIVATION" by Mirko Paiardini of Emory University School of Medicine, Atlanta, GA, USA

ORAL ABSTRACT: HIV/SIV AND THE IMMUNE SYSTEM: AN INTIMATE DANCE

"FTY720 LIMITS T FOLLICULAR HELPER CELL INFECTION IN LYMPHOID SITES OF SIV PERSISTENCE" by Maria Pino of Yerkes National Primate Research Center, Atlanta, GA, USA

ORAL ABSTRACT: HIV/SIV AND THE IMMUNE SYSTEM: AN INTIMATE DANCE

"TRANSCRIPTIONAL SIGNATURE OF LYMPH NODE CD8+ T CELLS IN HIV ELITE CONTROLLERS" by Son Nguyen of University of Pennsylvania, Philadelphia, PA, USA

ORAL ABSTRACT: HIV/SIV AND THE IMMUNE SYSTEM: AN INTIMATE DANCE

"CHARACTERIZING THE PROVIRAL LANDSCAPE IN HIV-1 ELITE CONTROLLERS" by Chenyang Jiang of Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA

ORAL ABSTRACT: HIV/SIV AND THE IMMUNE SYSTEM: AN INTIMATE DANCE

"INTERFERON Α2B REDUCES INDUCIBLE CD4-ASSOCIATED HIV IN ART-SUPPRESSED INDIVIDUALS" by Livio Azzoni of The Wistar Institute, Philadelphia, PA, USA

ORAL ABSTRACT: HIV/SIV AND THE IMMUNE SYSTEM: AN INTIMATE DANCE

"NEF-STOP REPAIR DYNAMICS, BUT NOT ANTI-Α4Β7, INFLUENCE POSTTREATMENT VIRAL CONTROL" by Michele Di Mascio of NIAID, Rockville, MD, USA

ORAL ABSTRACT: ANTIRETROVIRAL CLINICAL TRIALS AND RESISTANCE

"SEARCH INTERVENTION REDUCES MORTALITY AT A POPULATION LEVEL IN MEN WITH LOW CD4 COUNT" by Moses R. Kamya of Makerere University College of Health Sciences, Kampala, Uganda

ORAL ABSTRACT: ANTIRETROVIRAL CLINICAL TRIALS AND RESISTANCE

"LONG-ACTING CABOTEGRAVIR + RILPIVIRINE AS MAINTENANCE THERAPY: ATLAS WEEK 48 RESULTS" by Susan Swindells of University of Nebraska Medical Center, Omaha, NE, USA

ORAL ABSTRACT: ANTIRETROVIRAL CLINICAL TRIALS AND RESISTANCE

"LONG-ACTING CABOTEGRAVIR + RILPIVIRINE FOR HIV MAINTENANCE: FLAIR WEEK 48 RESULTS" by Chloe Orkin of Barts Health NHS Trust, London, United Kingdom

ORAL ABSTRACT: ANTIRETROVIRAL CLINICAL TRIALS AND RESISTANCE

"SAFETY AND PK OF SUBCUTANEOUS GS-6207, A NOVEL HIV-1 CAPSID INHIBITOR" by Jennifer E Sager of Gilead Sciences, Foster City, CA, USA

ORAL ABSTRACT: ANTIRETROVIRAL CLINICAL TRIALS AND RESISTANCE

"A PHASE IIA STUDY OF NOVEL MATURATION INHIBITOR GSK2838232 IN HIV PATIENTS" by Edwin DeJesus of Orlando Immunology Center, Orlando, FL, USA

ORAL ABSTRACT: ANTIRETROVIRAL CLINICAL TRIALS AND RESISTANCE

"SYSTEMATIC DETERMINATION OF IN VITRO HIV-1 INTEGRASE RESISTANCE FROM CLINICAL SAMPLES" by Aniqa Shahid of British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada

ORAL ABSTRACT: ANTIRETROVIRAL CLINICAL TRIALS AND RESISTANCE

"DTG VS LPV/R (DAWNING): EFFICACY BY BASELINE NRTI RESISTANCE AND SECOND-LINE NRTI USE" by Dannae Brown of ViiV Healthcare, Surry Hills, NSW, Australia

ORAL ABSTRACT: ANTIRETROVIRAL CLINICAL TRIALS AND RESISTANCE

"THERAPEUTIC ACTIVITY OF PGT121 MONOCLONAL ANTIBODY IN HIV-INFECTED ADULTS" by Kathryn E. Stephenson of Beth Israel Deaconess Medical Center, Boston, MA, USA

ORAL ABSTRACT: PROGRAMMATIC AND SCIENTIFIC ISSUES IN IMPLEMENTING HIV TREATMENT AND MONITORING

"MORTALITY REDUCTION IN WESTERN KENYA DURING SCALE-UP OF HIV TREATMENT, 2011-2016" by Emily C. Zielinski-Gutierrez of US Centers for Disease Control and Prevention, Nairobi, Kenya

ORAL ABSTRACT: PROGRAMMATIC AND SCIENTIFIC ISSUES IN IMPLEMENTING HIV TREATMENT AND MONITORING

"OPIOID OVERDOSE DEATHS AMONG PERSONS WITH HIV INFECTION, UNITED STATES, 2011-2015" by Karin A. Bosh of Centers for Disease Control and Prevention, Atlanta, GA, USA

ORAL ABSTRACT: PROGRAMMATIC AND SCIENTIFIC ISSUES IN IMPLEMENTING HIV TREATMENT AND MONITORING

"EARLY MORTALITY IN HIV-INFECTED PATIENTS INITIATING ART WITHOUT A PRETHERAPY CD4" by Kombatende Sikombe of Centre for Infectious Disease Research in Zambia, Lusaka, Zambia

ORAL ABSTRACT: PROGRAMMATIC AND SCIENTIFIC ISSUES IN IMPLEMENTING HIV TREATMENT AND MONITORING

"UTILITY OF CD4 CELL COUNT MONITORING IN BOTSWANA: ANALYSIS OF ROUTINE LABORATORY DATA" by Tshepo Botho Leeme of Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana

ORAL ABSTRACT: PROGRAMMATIC AND SCIENTIFIC ISSUES IN IMPLEMENTING HIV TREATMENT AND MONITORING

"TRENDS IN CD4 AND VIRAL LOAD TESTING IN SOUTHERN AFRICA: ANALYSIS OF 6 COUNTRIES" by Matthias Egger of University of Bern / Switzerland, Bern, Switzerland

ORAL ABSTRACT: PROGRAMMATIC AND SCIENTIFIC ISSUES IN IMPLEMENTING HIV TREATMENT AND MONITORING

"HIGH LEVELS OF DRUG RESISTANCE AMONG ART-EXPERIENCED HOSPITALIZED PATIENTS" by Claire Bossard of Médecins Sans Frontières, Cape Town, South Africa

ORAL ABSTRACT: PROGRAMMATIC AND SCIENTIFIC ISSUES IN IMPLEMENTING HIV TREATMENT AND MONITORING

"HIV DRUG RESISTANCE IN SOUTH AFRICA: RESULTS FROM A POPULATION-BASED HOUSEHOLD SURVEY" by Sizulu Moyo of Human Sciences Research Council, Cape Town, South Africa

ORAL ABSTRACT: PROGRAMMATIC AND SCIENTIFIC ISSUES IN IMPLEMENTING HIV TREATMENT AND MONITORING

"DURATION OF INFECTIOUSNESS AMONG PERSONS WITH HIV DIAGNOSED DURING 2012-2016" by Nicole Crepaz of Centers for Disease Control and Prevention, Atlanta, GA, USA